热搜第一！股价大跌，霸王茶姬回应“咖啡因”

Core Viewpoint - The stock price of Bawang Chaji has significantly dropped due to a caffeine controversy, reaching a new low since its IPO, which has sparked widespread discussion on social media [1][3][7]. Group 1: Stock Performance - On December 27, Bawang Chaji's stock was trending on Weibo, indicating heightened public interest and concern [2]. - The company's stock fell by nearly 16% during trading, closing at $11.90 per share, which is over 64% lower than its price on the first day of trading in April [7]. - The stock's 52-week high was $41.80, while the low was $10.26, reflecting significant volatility [8]. Group 2: Caffeine Controversy - The controversy began when a self-media personality suggested that high-caffeine beverages like Bawang Chaji's products are "skirting the edge of being a drug" [3]. - Many consumers reported adverse effects after consuming Bawang Chaji's drinks, including insomnia and palpitations [3]. - In response to the controversy, Bawang Chaji acknowledged the concerns and stated that they would take legal action against false information [5]. Group 3: Company Response and Future Plans - Bawang Chaji emphasized that their tea drinks have caffeine levels comparable to a latte and significantly lower than an Americano, while also highlighting the health benefits of tea [9][10]. - The company has introduced a product called "Light Caffeine · Boya Jue Xuan," which reduces caffeine content by approximately 50% while maintaining the core flavor of the tea [11]. - Bawang Chaji is exploring the possibility of creating caffeine-free tea options to cater to consumers sensitive to caffeine [9][12].